Combination of anti-FGFR4-antibody and bile acid sequestrant
AssigneesDaiichi Sankyo Europe GmbH, Daiichi Sankyo Company, Limited
InventorsReimar Abraham, Mauricio Redondo-Müller
Life of this patent
Estimating the term…
Abstract
The present invention relates to the amelioration of toxic effects that are caused by therapies aimed at FGFR4-inhibition. In particular, the invention relates to the combination of FGFR4 inhibitors and agents capable of reducing bile acid levels and to the use thereof in the treatment of diseases.
Claims8
A pharmaceutical composition or kit comprising an anti-FGFR4 antibody in combination with a bile acid sequestrant, wherein (i) the anti-FGFR4 antibody comprises a heavy chain variable region according to SEQ ID NO:
- 54 and a light chain variable region according to SEQ ID NO:
- 62, and (ii) the bile acid sequestrant comprises colestyramine.
A pharmaceutical composition or kit comprising an anti-FGFR4 antibody in combination with a bile acid sequestrant, wherein (i) the anti-FGFR4 antibody comprises a heavy chain comprising a CDRH1 as shown in SEQ ID NO:
- 3, a CDRH2 as shown in SEQ ID NO:
- 8 and a CDRH3 as shown in SEQ ID NO:
- 15 and a light chain comprising a CORL1 as shown in SEQ ID NO:
- 23, a CDRL2 as shown in SEQ ID NO:
- 25 and a CDRL3 as shown in SEQ ID NO:
- 30, and (ii) the bile acid sequestrant comprises colestyramine.
Dependencies are inferred from the claim text.